Although hematopoietic stem cells (HSC) are the best-characterized and the most clinically used adult stem cells, efforts are still needed to understand how to best ex vivo expand these cells. Here we present our unexpected finding that OCT4 is involved in the enhancement of cytokine-induced expansion capabilities of human cord blood (CB) HSC. Activation of OCT4 by OAC1 in CB CD34 + cells enhanced ex vivo expansion of HSC, as determined by a rigorously defined set of markers for human HSC, and in vivo short-term and long-term repopulating ability in NSG mice.
Introduction
Hematopoietic stem cells (HSC) are responsible for maintaining and replenishing all blood cell lineages during a lifetime. Allogeneic hematopoietic cell transplantation (HCT) is well established as a clinical means to treat patients with hematologic disorders and cancer. Human cord blood is an alternative source of HSC for transplantation 1 -3 ; the advantages of using CB as a hematopoietic source for HCT are: easy accessibility of banked HLA-typed CB and, decreased graft-versus-host disease. However, numbers of nucleated cells retrieved, as well as limited numbers of HSC/progenitor (HPC) cells present, during collection may be problematic for treatment of adult patients with single CB HCT. One means to address the problem of limiting numbers of HSC/HPC is to ex vivo expand these cells for potential clinical use. While progress has been made in this endeavor 1 , 4 , 5 , there is still a clinically relevant need for additional means to ex vivo expand human HSC and HPC.
The POU domain family transcriptional factor Octamer binding protein 4 (OCT4) is well defined as a master regulator for maintenance of totipotency and pluripotency 6 . In embryonic stem cells, OCT4, SOX2 and NANOG form a regulatory circuitry to orchestrate self-renewal and suppress differentiation 7 . In vivo expression of OCT4 and three other transcriptional factors enable reprogramming of somatic cells to induced pluripotent stem cells 8 . Surprisingly, ectopic expression of OCT4, together with cytokine treatment, allowed generation of human hematopoietic progenitor cells from fibroblasts, suggesting an unexpected role of OCT4 during hematopoietic fate transition 9 . Recently, a small molecule library screen identified Oct4-activating compound 1 (OAC1) as a reagent to increase the expression of the endogenous Oct4. OAC1 facilitated the reprogramming of cells by enhancing efficiency and shortening the reprogramming time 10 . Additionally, Oct4 gene expression has been reported in a variety of adult stem cells, including breast stem cells, pancreatic stem cells, liver stem cells, mesenchymal stem cells and HSC suggesting that OCT4 might also function in somatic stem cells 11 -13 . However, the functions of OCT4 in somatic stem cells, especially in HSC are largely unknown.
In this study we hypothesized that OCT4 is involved in HSC function and expansion, and thus we evaluated the effects of OAC1 on ex vivo culture of CB CD34 + cells in the presence of a cocktail of cytokines known to enhance ex vivo expansion of human HSCs. We found that CB CD34 + cells treated with OAC1 showed a significant increase above that of this cytokine cocktail in the numbers of rigorously defined HSC by phenotype and in vivo repopulating capacity in NSG mice, and in numbers of multipotential, erythroid and granulocyte macrophage progenitors as determined by colony assays. We identified HOXB4 as a crucial downstream target of OCT4 and showed that OCT4-HOXB4 axis was essential for OAC1-mediated HSC expansion. We did not detect leukemic transformation of engrafted cells within the time frame of our experimental observations nor did the cells form teratomas in mice. Our data show, for the first time, a functional link between OCT4 expression and HSC function, and suggest the potential clinical application of using OAC1, or next generation OCT4 activators, to ex vivo expand human HSC.
Materials and Methods

Mice
All experimental procedures with mice were approved by The Institutional Animal Care and Use Committee of the Indiana University School of Medicine. NSG (NOD.CgPrkdc scid Il2rg tm1Wjl /Sz; 8-10 weeks old) mice were obtained from an on-site core breeding colony supported at our NIDDK Center of Excellence in Molecular Hematology and the NCI-designated Indiana University Simon Cancer Center.
In vitro cell cultures
Normal human cord blood was provided by CordUse, a cord blood banking company. Mononuclear cells were isolated by density gradient centrifugation over Ficoll-Paque Plus (GE Healthcare). CD34 + cells were obtained by immunomagnetic selection (Miltenyi Biotec, Auburn, CA, USA) over two sequential columns. This yields 90-98% purity of CD34 + cells. CD34 + cells were then cultured in RPMI-1640 medium containing 10% FBS, 100 ng/mL stem cell factor (SCF), thrombopoietin (TPO), Fms-like tyrosine kinase 3 ligand (Flt3L), in the presence of 500nM OAC1 (Xcessbio, San Diego, CA, USA) or with a vehicle control (DMSO). For lentiviral vector transduction, CB CD34 + cells were transduced with lentiviral vector pCSC-GW and pCSC-OCT4 (OCT4 cDNA was cloned into AgeI site in pCSC-GW plasmid) as previous described 14 , transduced CD34 + cells were cultured for 4 days before flow analysis.
Flow cytometry and antibodies
Cells were stained at 4°C for 30 minutes with the following antibodies: Lineage cocktail (Lin)-FITC, CD34-APC (581), CD38-PE (HIT2), CD45RA-PECF594 (HI100), CD90-PEcy7 (5E10), and CD49f-PerCPcy5.5 (GoH3) for phenotypic analysis of HSC and HPC; CD3-FITC (UCHT1), CD19-PE (HIB19), CD33-FITC (WM53), CD45-APC (HI30) were used for in vivo transplantation. All the above antibodies were purchased from BD Bioscience. For intracellular staining, CD34 + cells were fixed, permeabilized and stained with OCT4 (C-10, Santa Cruz), SOX2 (57CT23.3.4, Abcam), NANOG (H-155, Santa Cruz) or HOXB4 (EP1919Y, Abcam) primary antibodies. Cells were washed and then stained with FITC-conjugated secondary antibody for 30 minutes on ice, light protected. Flow analysis was performed with a BD Bioscience LSR II and FlowJo software. The negative portion was determined by using relevant isotype antibody controls.
In vitro colony-forming unit (CFU) assay
CB CD34 + cells were seeded in triplicate in 1.0 mL methylcellulose culture medium supplement with 30% FBS, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, and recombinant human cytokines: 1 U/mL erythropoietin, 50 ng/mL SCF, 10 ng/mL interleukin-3 (IL-3), and 10 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF). The number of colonies was scored at Day 14 with an inverted microscope. All cell cultures were incubated in a 5%O 2 /5%CO 2 humidified chamber.
In vivo transplantation
Transplantation of human cells into NSG mice was done as described previously 14 , 15 .
Briefly, 8-10 week old NSG mice were sublethally irradiated (350cGy; 137 Cs source, single dose) and transplanted with progeny of 50000 OAC1 or vehicle control treated CB CD34 + cells within 24h after irradiation. Peripheral bloods were collected at various time points by tail-vein bleeding. The blood samples were treated with RBC lysis buffer and then washed in PBS+1% BSA buffer before staining. Peripheral blood collected from untransplanted NSG mouse was used as a negative control. Mice were sacrificed 16 weeks after transplantation. For long-term engraftment assay, 2×10 6 BM cells from the primary recipient mice were infused into secondary recipient mice. These mice were also sacrificed 16 weeks after transplantation. BM cells were stained and analyzed by flow cytometry as described above.
Limiting dilution analysis
The frequency of human SRCs in uncultured CD34 + cells and the progeny of an equivalent number of CD34 + cells that were ex vivo expanded in the presence of vehicle control or OAC1 were analyzed by limiting dilution assay as reported by others 4 . Increasing doses of uncultured CD34 + cells (500, 2500, 5000) or the progeny of an equivalent number of CD34 + cells were infused into NSG mice. These mice were sacrificed 12 weeks after transplantation. The HSC frequency was calculated using L-Calc software (StemCell Technologies Inc.) and plotted using ELDA software (bioinf.wehi.edu.au/software/elda/).
siRNA-mediated knockdown analysis
CB CD34 + cells were transfected with 40nM OCT4 (sc-36123), HOXB4 (sc-38692) or scrambled siRNA (sc-37007) according to the manufacturer's instructions (Santa cruz). OCT4 and HOXB4 protein expression levels were assessed following siRNA knockdown. Cells treated with siRNA were stained after 4 days of culture in the presence of vehicle control or OAC1, and analyzed by flow cytometry for HSC fraction.
In vivo teratoma formation assay 1×10 6 CD34 + cells from vehicle control cultures or cultures containing OAC1 or 1×10 6 human H9 ES cells were subcutaneously injected into 6-week-old, Athymic nude mice 16 .
The resulting teratomas were removed 6 weeks later. Samples from the teratomas were paraffin-embedded and serially sectioned using microtome (Leica Microsystems, Wetzlar, Germany). To analyze the three germ-layer lineage cells derived from injected H9 ES cells in the teratomas, sectioned slides were stained with hematoxylin and eosin (HE stain). Images were analyzed using an inverted microscope system (Nikon).
Statistical analysis
Results are expressed as mean values ± standard deviation. P value less than 0.05 (two tailed student t test) was considered as statistically significant.
Results
OAC1 treatment results in increased numbers of phenotypic HSC and functional HPC
To test whether activation of OCT4 is involved in expansion of HSC, CD34 + cells from human cord blood were cultured for 4 days in medium containing 100 ng/mL of SCF, TPO and Flt3L with and without the OCT4 activator compound OAC1 10 . A concentration of 500nM OAC1, was the most effective for ex vivo HSC expansion (Supplementary Figure   1A) . The protein level of OCT4 expression greatly increased after culture of CB CD34 + cells with OAC1 ( Figure 1a ). Since OCT4, SOX2 and NANOG form an autoregulatory feedback loop, we also observed upregulation of SOX2 and NANOG in OAC1-treated cells ( Supplementary Figures 2A and 2B ). To assess whether OAC1 affects the epigenetic states in CD34 + cells, we examined the levels of Histone 3 lysine 4 trimethylation (H3K4me3) and Histone 3 lysine 9 trimethylation (H3K9me3) in OAC1-treated cells. H3K4me3 is known to be associated with transcriptional active state, while H3K9me3 has been well characterized as a mark of transcriptional inactive state 17 . The levels of H3K4me3 and H3K9me3 did not show significant difference in OAC1-treated cells (Supplementary Figures 2C and 2D ), suggesting that OAC1 did not affect the epigenetic marks of these cells.
We firstly observed that numbers of CD34 + CD38 − cells significantly increased in the OAC1 treated group after culture compared with the vehicle treated group (Figures 1b and c) . We then carefully examined the effect of OAC1 in a more rigorously defined most primitive (Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + ) HSC population 18 . We found that there was a 7.6 fold increase in these cells in the OAC1 treated group compared with uncultured Day0 group, and a 2.8 fold increase compared with vehicle treated group (Figures 1b and d) . To further confirm the role of OCT4 during ex vivo HSC culture, we performed OCT4 overexpression in CB CD34 + cells using lentiviral vectors and found that overexpression of OCT4 also resulted in significant increase in the number of phenotypic HSC compared to control vectors (Figure 1e ). There was also a significant increase in phenotypic HSC for 7 days in the presence of OAC1 (Supplementary Figure 3A) . Also, the effect of OAC1 was reproducible when CB CD34 + cells were cultured in serum-free medium Stemline II (Supplementary Figure 3B) . We also noticed that the number of phenotypically-defined endothelial progenitor cells (EPC, CD133 + CD309 + CD34 + ) significantly increased in the OAC1 treated group, while the number of mesenchymal stromal cells (MSC, CD45 − CD73 + CD105 + CD90 + ) did not show significant differences in the OAC1 treated group (Supplementary Figure 3C and 3D) . Therefore, our results suggest that OAC1 facilitates cytokine stimulated ex vivo CB HSC expansion.
To assess whether OAC1 also enhanced cytokine stimulated ex vivo expansion of HPC, CB CD34 + cells treated with the cytokine combination with either OAC1 or vehicle control were seeded in semisolid methylcellulose culture medium and cultured for 14 days in the presence of a maximally stimulatory combination of cytokines (Erythropoietin, SCF, IL-3 and GM-CSF). OAC1 significantly increased numbers of granulocyte/macrophage (CFU-GM), erythroid (BFU-E), and granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) progenitors after 4 days ex vivo culture (Figure 2a ), demonstrating that OAC1 also enhances cytokine-stimulated ex vivo expansion of functionally recognizable HPC. To further confirm that OAC1 enhances ex vivo expansion of HPC, suboptimal cytokine doses were either employed during ex vivo expansion (SCF, TPO and Flt3L), or during the CFU assay (Erythropoietin, SCF, IL-3 and GM-CSF). Significant increases in CFU numbers in OAC1 treated group were observed in both situations (Figure 2b and 2c) , suggesting that OAC1 enhances ex vivo expansion of HPC with both full and suboptimal cytokine doses in the expansion and colony forming phases.
Culture of CB CD34 + with OAC1 enhances short and long-term engrafting HSC
The human cell immune-deficient mouse engraftment assay currently serves as the best model for determining functionality of human HSC 19 . To evaluate the functionality of OAC1-treated CD34 + cells, sublethally irradiated NSG mice were transplanted with the progeny of 50000 CB CD34 + cells that had been cultured for 4 days with SCF, TPO and Flt3L and with OAC1 or vehicle control. We observed significantly increased engraftment of OAC1 treated CB cells in primary recipients, compared to the vehicle control group (Figures  3a and 3b) , with across the board increase for human B cells, T cells and myeloid cells in the bone marrow (BM) of primary recipients (Figure 3c ). To determine whether OAC1-expanded cells had self-renewal capability, we transplanted BM cells from primary NSG mice 16 weeks after transplantation into secondary sublethally irradiated NSG mice. We found that the OAC1 expanded group also resulted in greater engraftment of human CD45 + cells in secondary mouse recipients (Figure 3d ), suggesting that we had increased the longterm engrafting capacity of self-renewing HSC after OAC1 treatment.
To assess the degree of HSC expansion by OAC1 treatment, we did a limiting dilution assay to compare the frequency of SRCs in Day 0 uncultured CD34 + cells, in the progeny of an equivalent number of cells in the presence of vehicle control, or OAC1 after 4 days ex vivo culture (Table 1) (Table 2) . So OAC1 treatment resulted in 3.5 fold increase in the number of SRCs compared with that in Day 0 uncultured CD34 + cells and 6.3 fold increase compared with that in cells treated with control vehicle (Figure 4b ). Our data demonstrate that CB CD34 + cells cultured with OAC1 results in a significant expansion of SRC numbers.
HOXB4 is essential for OAC1-mediated expansion of cord blood HSC
HOXB4 is a homeobox transcriptional factor that appears to be an essential regulator of HSC self-renewal; overexpression of HOXB4 resulted in high-level ex vivo HSC expansion 20 , 21 . Also, it has been reported that OCT4 could bind to the promoter region of HOXB4 at the site of 2952 bp from transcription start point 7 . So, we hypothesized that activation of OCT4 might work through upregulation of HOXB4 expression to ex vivo expand HSC. The expression level of HOXB4 in human CB CD34 + cells was assessed by flow cytometry after 4 days treatment with OAC1 or vehicle control. We observed that the expression of HOXB4 was significantly increased after culture of CB CD34 + cells with OAC1 compared to vehicle control (Figure 5a ). To further confirm a functional link between upregulation of HOXB4 in OAC1-treated cells and the expansion of primitive HSC, we transfected CD34 + cells with HOXB4 siRNA. siRNA-mediated HOXB4 knockdown led to a significant reduction in the absolute number of Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + cells in OAC1-treated cells (Figure 5b ), suggesting HOXB4 is essential for the generation of primitive HSC in OAC1-treated cells. Next, we asked whether OCT4 is required for the upregulation of HOXB4 in OAC1-treated cells by using OCT4 siRNA. Similar with HOXB4 siRNA, knockdown of OCT4 led to a significant reduction in phenotypic HSC (Figure 5b ).
Furthermore, we found that siRNA mediated inhibition of OCT4 also resulted in marked reduction of HOXB4 expression in OAC1-treated cells (Figure 5c ), while knockdown of HOXB4 did not affect the expression of OCT4 in OAC1-treated cells (Figure 5d ), suggesting HOXB4 is downstream of OCT4 during ex vivo expansion of CB HSC.
Additionally, we tested whether knockdown of HOXB4 affects OAC1-mediated expansion of HPC. CB CD34 + cells were transfected with HOXB4 siRNA or OCT4 siRNA and then cultured with the cytokine combination with either OAC1 or vehicle control for 4 days. The treated cells were seeded in semisolid methylcellulose culture medium and cultured for 14 days. We observed that knockdown of HOXB4 or OCT4 also blocked OAC1-mediated increased numbers of CFU-GM and CFU-GEMM colonies (Supplementary Figure 4A ). To further demonstrate that OCT4 binds to the HOXB4 promoter region in HSC, we carried out a ChIP analysis using anti-OCT4 antibody. Consistently, we found that immunoprecipitation with OCT4 antibody showed marked enrichment for the −3000 bp of the HOXB4 promoter region (Supplementary Figure 4B) . Taken together, our data indicate that OAC1 treatment leads to OCT4-mediated upregulation of HOXB4, which is essential for the generation of human CB Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + HSC.
OAC1 treated CD34 + cells did not form teratoma in vivo
To exclude the possibility that the expanded cells contained leukemogenic potential, we followed the survival ratio of NSG mice transplanted with vehicle control or OAC1 treated CD34 + cells. Within the time frame of our experiments (up to 16 weeks post-transplant), there was no significant difference between vehicle control group and OAC1 treated group (Supplementary Figure 5 , p>0.05), nor did we detect any evidence of the generation of leukemic cells, suggesting that OAC1 treatment did not cause malignant transformation of CD34 + cells during our observation periods.
Since OCT4 expression has been associated with induction of pluripotency that could potentially lead to the formation of teratomas, CD34 + cells from vehicle control cultures, OAC1 treatment cultures or human H9 ES cells were each injected subcutaneously into nude mice and were examined after 6 weeks. Teratomas, containing tissue from all three germ layers, formed from the H9 ES cells (Supplementary Figure 6 ) that were not observed in animals injected with CD34 + cells from vehicle control cultures or OAC1 treatment cultures.
Discussion
Understanding the regulation of HSC by intrinsic and extrinsic factors is important for improving HCT. Although many extrinsic factors have been identified as regulators of HSC, such as cytokines 22 , Notch ligands 23 , Wnt ligands 24 , and Angiopoietins 25 , to the best of our knowledge, HOXB4 is the only intrinsic factor that shows positive effects on ex vivo HSC expansion. Here we demonstrate that OCT4 is another intrinsic factor that plays an important role in HSC expansion. By utilization of OAC1, we observed significant increase in the number of phenotypic HSC, HPC, and short-term and long-term HSC in vivo repopulating capability.
We used a simple HSC culture medium containing SCF, TPO and Flt3L, with or without serum, and in this system we observed OCT4-mediated HSC expansion in 4 days. The quality of the OAC1-expanded HSC did not appear to be impaired, as they showed multilineage repopulating capability. Besides, all NSG mice transplanted with OAC1-expanded cells remained healthy and without any obvious disorders. Our study also followed engraftment in secondary transplanted animals for 4 months after 4-months engraftment in primary mice, suggesting that the enhancement was for long-term repopulating, selfrenewing HSC. While we did not detect any leukemic transformation of cells engrafted with ex-vivo cultured CD34 + CB cells for up to 16 weeks, and did not detect any teratoma formation by these cultured cells when injected into mice, we can not completely rule out the possibility that the ex vivo expanded cells contained leukemogenic potential. This is always the concern for all the ex vivo modified cells regardless of how they are expanded.
Future studies on non human primates and humans may be needed before full clinical safety is known.
How physiological HSC self-renewal is regulated remains incompletely understood. Our data showed, for the first time, that overexpression of OCT4 enhanced ex vivo HSC expansion and suggest that OCT4 plays an essential role in HSC self-renewal. Direct generation of progenitors of hematopoietic fate from human dermal fibroblasts by ectopic expression of OCT4 has recently been reported 9 , and this finding reinforces our current study, that indicates OCT4 as a component in HSC biology. OCT4 expression in somatic stem cells has been described 11 -13 , however, the links to functional activities are largely missing. Previously, it was reported that Oct4 gene ablation in mice did not show significant difference in various tissues, including intestine, bone marrow and brain 26 . However, these results could be explained by the functional redundancy within the Oct family and Pou domain family and could not rule out the possibility that overexpression of Oct4 would have impact in these tissues. Recent reports also showed that overexpression of OCT4 increased the proliferative capacity and functionality of mesenchymal stem cells 27 , 28 . Our data indicate activation of OCT4 by OAC1 or lentiviral vector is sufficient to enhance HSC expansion while preserving the functionality. This information raises a number of important possibilities regarding the function of OCT4 in other types of somatic stem cells.
The human homeodomain containing transcription factor HOXB4 was the first gene shown to dramatically expand murine HSC when ectopically expressed 20 . Ectopic expression of HOXB4 also enhanced the generation of definitive HSC from murine ES cells 29 . TAT-HOXB4 and degradation-resistant HOXB4 variant also markedly enhanced ex vivo expansion of human HSC 21 , 30 . These studies demonstrated that the function of HOXB4 is important for HSC. We found that the expression of HOXB4 protein was largely increased in OAC1-treated CD34 + cells, and knockdown of HOXB4 blocked the ex vivo expansion of CB HSC by OAC1, suggesting HOXB4 as a key component in mediating OCT4 function in ex vivo HSC expansion.
As reported, detection of OCT4 expression by RT-PCR could be misled by pseudogene transcripts 31 , so we examined the protein expression level of OCT4 in CB CD34 + cells and showed that significant elevation of OCT4 protein expression was observed in CB CD34 + cells treated with OAC1. Recently, it was reported that valproic acid treatment also led to upregulation of OCT4, SOX2 and NANOG, which is essential for the valproic acidmediated expansion of cord blood stem cells 32 . In our study, we emphasized that the function of OCT4 was crucial during ex vivo CB HSC expansion and demonstrated that HOXB4 was a important downstream target in mediating ex vivo HSC expansion by OCT4.
In summary, overexpression of OCT4 by OAC1 regulates ex vivo HSC expansion by regulating HOXB4 expression, the data presented here suggest the importance of OCT4 in HSC function. It would be interesting to explore the potential of OAC1 treatment for translation to clinical HSC transplantation and to search for better structural analogs of OAC1 that will be more effective in enhancing ex vivo HSC expansion. The approach used in our report may have the potential to generate sufficient numbers of in vivo repopulating HSC to facilitate allogeneic CB HCT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Full dose: 100ng/mL SCF, 100ng/mL TPO and 100ng/mL Flt3L; 1/2 dose: 50ng/mL SCF, 50ng/mL TPO and 50ng/mL Flt3L; 1/4 dose: 25ng/mL SCF, 25ng/mL TPO and 25ng/mL Flt3L; 1/8 dose: 12.5ng/mL SCF, 12.5ng/mL TPO and 12.5ng/mL Flt3L. * indicates p<0.05, ** indicates p<0.01, N.S. indicates p>0.05. (c) CFU numbers in the progeny of 1000 CD34 + cells that were expanded in the presence of vehicle control or OAC1 for 4 days and different doses of cytokines were only employed during CFU assay. Full dose: 1 U/mL erythropoietin, 50 ng/mL SCF, 10 ng/mL IL-3, and 10 ng/mL GM-CSF; 1/2 dose: 0.5 U/mL erythropoietin, 25 ng/mL SCF, 5 ng/mL IL-3, and 5 ng/mL GM-CSF; 1/4 dose: 0.25 U/mL erythropoietin, 12.5 ng/mL SCF, 2.5 ng/mL IL-3, and 2.5 ng/mL GM-CSF; 1/8 dose: 0.125 U/mL erythropoietin, 6.25 ng/mL SCF, 1.25 ng/mL IL-3, and 1.25 ng/mL GM-CSF. * indicates p<0.05, ** indicates p<0.01, N.S. indicates p>0.05. Data represent the mean ± s.d. 
